Basement membrane and growth factor gene expression in normal and diabetic human retinas

Current Eye Research

Volumn 18, Issue 6, 1999, Pages 490-499

  Spirin, Konstantin S ^a   Saghizadeh, Mchrnoosh ^a   Lewin, Sheryl L ^a   Zardi, Luciano ^b   Kenney, M Cristina ^a   Ljubimov, Alexander V ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Basement membrane; Diabetic retinopathy; Fibronectin; Gene expression; Placenta growth factor; Tenascin C; Vascular endothelial growth factor

Indexed keywords

BETA 2 MICROGLOBULIN; COMPLEMENTARY DNA; FIBRONECTIN; GROWTH FACTOR; MESSENGER RNA; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN RECEPTOR;

AGED; ANGIOGENESIS; ARTICLE; BASEMENT MEMBRANE; BLOOD VESSEL WALL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; RETINA; RETINA NEOVASCULARIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

AGED; AGED, 80 AND OVER; BASEMENT MEMBRANE; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBRONECTINS; GENE EXPRESSION; GROWTH SUBSTANCES; HUMANS; LYMPHOKINES; MALE; MIDDLE AGED; PREGNANCY PROTEINS; REFERENCE VALUES; RNA, MESSENGER; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032989727     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.18.6.490.5267     Document Type: Article

References (54)

1. Ljubimov AV, Burgeson RE, Butkowski RJ, Couchman JR, Zardi L, Ninomiya Y, Sado Y, Huang Z, Nesburn AB, Kenney MC. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem. 1996;44:1469-1479.
2. Williamson JR, Tilton RG, Chang K, Kilo C. Basement membrane abnormalities in diabetes mellitus: relationship to clinical microangiopathy. Diabetes/Metabolism Revs. 1988;4:339-370.
3. Østerby R. Basement membrane morphology in diabetes mellitus. In: Rifkin H, Porte D, Jr. Diabetes Mellitus. Theory and Practice, 4th ed. New York-Amsterdam-London: Elsevier; 1990:220-233.
4. Grant MB, Ellis EA, Caballero S, Marnes RN. Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy. Exp Eye Res. 1996;63:233-244.
5. Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1990;108:869-872.
6. Grant M, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes 1986;35:416-420.
7. Meyer-Schwickerath R, Pfeiffer A, Blum WF, Freyberger H, Klein M, Lösche C, Röllmann R, Schatz H. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest. 1993;92:2620-2625.
8. Robinson GS, Aiello LP. Angiogenic factors in diabetic ocular disease: mechanisms of today, therapies for tomorrow. Int Ophthalmol Clin. 1998;38:89-102.
9. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes/Metabolism Revs. 1997;13:37-50.
10. Boulton M, Gregor Z, McLeod D, Charteris D, Jarvis-Evans J, Moriarty P, Khaliq A, Foreman D, Allamby D, Bardsley B. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol. 1997;81:228-233.
11. Khaliq A, Foreman D, Ahmed A, Weich H, Gregor Z, McLeod D, Boulton M. Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest. 1998;78:109-116.
12. Saghizadeh M, Khin HL, Bourdon MA, Kenney MC, Ljubimov AV. Novel splice variants of human tenascinC mRNA identified in normal and bullous keratopathy corneas. Cornea 1998; 17:326-332.
13. Ishiguro A, Spirin K, Shiohara M, Tobler A, Israel MA, Norton JD, Rigolet M, Shimbo T, Koeffler HP. Expression of Id2 and Id3 genes in human lymphocytes. Leukemia Res. 1995;19:989-996.
14. Kenney MC, Chwa M, Opbroek AJ, Brown DJ. Increased gelatinolytic activity in keratoconus keratocyte cultures. A correlation to an altered matrix metalloproteinase-2/tissue inhibitor of metalloproteinase ratio. Cornea 1994;13:114-124.
15. Balza E, Siri A, Ponassi M, Caocci F, Linnala A, Virtanen I, Zardi L. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett. 1993;332:39-43.
16. Siri A, Knäuper V, Veirana N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem. 1995;270:8650-8654.
17. Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol. 1998;152:1453-1462.
18. Tucker RP, Hammarback JA, Jenrath DA, Mackie EJ, Xu Y. Tenascin expression in the mouse: in situ localization and induction in vitro by bFGF. J Cell Sci. 1993;104:69-76.
19. Sakai T, Kawakatsu H, Ohta M, Saito M. Tenascin induction in tenascin nonproducing carcinoma cell lines in vivo and by TGF-β1 in vitro. J Cell Physiol. 1994;159:561-572.
20. LaFleur DW, Fagin JA, Forrester JS, Rubin SA, Sharifi BG. Cloning and characterization of alternatively spliced isoforms of rat tenascin. J Biol Chem. 1994;269:20757-20763.
21. Chiquet-Ehrismann R, Hagios C, Schenk S. The complexity in regulating the expression of tenascins. BioEssays 1995;17:873-878.
22. Ju H, Dixon IM. Extracellular matrix and cardiovascular diseases. Can J Cardiol. 1996;12:1259-1267.
23. Couchman JR, Beavan LA, McCarthy KJ. Glomerular matrix: synthesis, turnover and role in mesangial expansion. Kidney Int. 1994;45:328-335.
24. Yokoyama H, Deckert T. Central role of TGF-β in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Diabet Med. 1996;13:313-320.
25. Ljubimov AV, Saghizadeh M, Spirin KS, Khin HL, Lewin SL, Zardi L, Bourdon MA, Kenney MC. Expression of tenascin-C splice variants in normal and bullous keratopathy human corneas. Invest Ophthalmol Vis Sci. 1998;39:1135-1142.
26. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983;43:2796-2805.
27. Erickson HP. Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol. 1993;5:869-876.
28. Crossin KL. Tenascin: a multifunctional extracellular matrix protein with a restricted distribution in development and disease. J Cell Biochem. 1996;61:592-598.
29. Chiquet-Ehrismann R, Matsuoka Y, Hofer U, Spring J, Bernasconi C, Chiquet M. Tenascin variants: differential binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regul, 1991;2:927-938.
30. Deryugina EI, Bourdon MA. Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci. 1996;109:643-652.
31. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M. Focal adhesion integrity is down-regulated by the alternatively spliced domain of human tenascin. J Cell Biol. 1991;115:1127-1136.
32. Leprini A, Querze G, Zardi L. Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Perspect Dev Neurobiol. 1994;2:117-123.
33. Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci. 1995;108:797-809.
34. Jallo GI, Friedlander DR, Kelly PJ, Wisoff JH, Grumet M, Zagzag D. Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis. Neurosurgery 1997;41:1052-1059.
35. Kostianovsky M, Alba Greco M, Cangiarella J, Zagzag D. Tenascin-C expression in ultrstructurally defined angiogenic and vasculogenic lesions. Ultrastruct Pathol. 1997;21:537-544.
36. Zagzag D, Friedlander DR, Dosik j, Chikramane S, Chan W, Greco MA, Allen JC, Dorovini-Zis K, Grumet M. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res. 1996;56:182-189.
37. Mardon HJ, Grant RP, Grant KE, Harris H. Fibronectin splice variants are differentially incorporated into the extracellular matrix of tumorigenic and non-tumorigenic hybrids between normal fibroblasts and sarcoma cells. J Cell Sci. 1993;104:783-792.
38. Kosmehl H, Berndt A, Katenkamp D. Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects. Virchows Arch. 1996;429:311-322.
39. Kornblihtt AR, Pesce CG, Alonso CR, Cramer P, Srebrow A, Werbajh S, Muro AF. The fibronectin gene as a model for splicing and transcription studies. FASEB J. 1996;10:248-257.
40. Xia P, Culp LA. Adhesion activity in fibronectin's alternatively spliced domain EDa (EIIIA): complementarity to plasma fibronectin functions. Exp Cell Res. 1995;217:517-527.
41. Chen W, Culp LA. Adhesion mediated by fibronectin's alternatively spliced EDb (EIIIB) and its neighboring type III repeats. Exp Cell Res. 1996;223:9-19.
42. Manabe R, Ohe N, Maeda T, Fukuda T, Sekiguchi K. Modulation of cell-adhesive activity of fibronectin by the alternatively spliced EDA segment. J Cell Biol. 1997;139:295-307.
43. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994;59:612-618.
44. Karelina TV, Eisen AZ. Interstitial collagenase and the ED-B oncofetal domain of fibronectin are markers of angiogenesis in human skin tumors. Cancer Detect Prev. 1998;22:438-44.
45. Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F, Plouet J. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol. 1994;112:1476-1482.
46. Boulton M, Foreman D, Williams G, McLeod D. VEGF localisation in diabetic retinopathy. Br J Ophthalmol. 1998;82:561-568.
47. Hata Y, Nakagawa K, Ishibashi T, Inomata H, Ueno H, Sueishi K. Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch. 1995;426:479-486.
48. Sone H, Kawakami Y, Okuda Y, Kondo S, Hanatani M, Suzuki H, Yamashita K. Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells. Biochem Biophys Res Commun. 1996;221:193-198.
49. Hirata C, Nakano K, Nakamura N, Kitagawa Y, Shigeta H, Hasegawa G, Ogata M, Ikeda T, Sawa H, Nakamura K, Ienaga K, Obayashi H, Kondo M. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Müller cells. Biochem Biophys Res Commun. 1997;236:712-715.
50. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem. 1996;271:2746-2753.
51. Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes 1997;46(Suppl 2):S26-S30.
52. Behzadian MA, Wang XL, Shabrawey M, Caldwell RB. Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-β. Glia 1998;24:216-225.
53. Ogata N, Yamamoto C, Miyashiro M, Yamada H, Matsushima M, Uyama M. Expression of transforming growth factor-β mRNA in experimental choroidal neovascularization. Curr Eye Res. 1997;16:9-18.
54. Ozaki H, Okamoto N, Ortega S, Chang M, Ozaki K, Sadda S, Vinores MA, Derevjanik N, Zack DJ, Basilico C, Campochiaro PA. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. Am J Pathol. 1998;153:757-765.